Using natural killer cells to target and reduce HIV reservoirs
Harnessing adaptive NK cell transfer to deplete viral reservoirs
This study is exploring a new way to help people with HIV by using special immune cells called natural killer (NK) cells to find and destroy HIV-infected cells, which could lead to better treatments for managing the virus.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project ID | NIH-11060952 on NIH RePORTER |
What this research studies
This research investigates how natural killer (NK) cells can be harnessed to effectively target and eliminate HIV-infected cells. By activating these immune cells and transferring them into patients, the study aims to enhance the body's ability to recognize and destroy cells harboring the virus. The approach involves understanding the interactions between NK cell receptors and viral peptides, which could lead to innovative therapies for HIV. Patients may benefit from a potential new treatment that could reduce viral loads and improve immune responses.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who have not responded adequately to existing treatments.
Not a fit: Patients who are not infected with HIV or those with advanced AIDS may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking therapy that significantly reduces HIV reservoirs in patients.
How similar studies have performed: Previous research has shown promise in using NK cell therapies for targeting viral infections, indicating a potential for success in this novel approach.
Where this research is happening
Madison, United States
- University of Wisconsin-Madison — Madison, United States (Active)
Researchers
- Principal investigator: Evans, David T — University of Wisconsin-Madison
- Study coordinator: Evans, David T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.